Loading patent…
AssigneeMERZ PHARMA GmbH & CO. KGaA
InventorsJuergen Frevert, Fred Hofmann, Michael Schmidt, Manuela López De La Paz, Daniel Scheps
Estimating the term…
This invention relates to novel recombinant clostridial neurotoxins exhibiting increased duration of effect and to methods for the manufacture of such recombinant clostridial neurotoxins. These novel recombinant clostridial neurotoxins comprise a random coil domain, and the methods comprise the steps of inserting a nucleic acid sequence coding for a random coil domain into a nucleic acid sequence coding for a parental clostridial neurotoxin and expression of the recombinant nucleic acid sequence comprising the random coil domain-coding sequence in a host cell. The invention further relates to novel recombinant single-chain precursor clostridial neurotoxins used in such methods, nucleic acid sequences encoding such recombinant single-chain precursor clostridial neurotoxins, and pharmaceutical compositions comprising the recombinant clostridial neurotoxin with increased duration of effect.
A recombinant clostridial neurotoxin comprising a protein segment comprising an amino acid sequence consisting of at least 50 amino acid residues, wherein (i) said protein segment consists of alanine, serine and proline residues;
A pharmaceutical composition comprising a recombinant clostridial neurotoxin comprising a protein segment comprising an amino acid sequence consisting of at least 50 amino acid residues,
A recombinant single-chain clostridial neurotoxin precursor for a disulfide-linked di-chain clostridial neurotoxin, comprising a functionally active clostridial neurotoxin light chain, a functionally active neurotoxin heavy chain, a loop region linking the C-terminus of the light chain with the N-terminus of the heavy chain, and a protein segment comprising an amino acid sequence consisting of at least 50 amino acid residues,
Dependencies are inferred from the claim text.